L J Kay1, A Rostami-Hodjegan, S K Suvarna, P T Peachell. 1. Academic Unit of Molecular Pharmacology, University of Sheffield, The Royal Hallamshire Hospital (Floor M), Sheffield, S Yorks S10 2JF, UK.
Abstract
BACKGROUND AND PURPOSE: Previous studies have shown that beta(2)-adrenoceptor-mediated responses in human lung mast cells are highly variable. The aims of the present study were to establish whether polymorphisms of the beta (2)-adrenoceptor gene (ADRB2) influence this variability in (a) beta(2)-adrenoceptor-mediated inhibition and (b) desensitization of beta(2)-adrenoceptor-mediated responses in human lung mast cells. EXPERIMENTAL APPROACH: Mast cells were isolated from human lung tissue. The inhibitory effects of the beta-adrenoceptor agonist, isoprenaline (10(-10)-10(-5) M), on IgE-mediated histamine release from mast cells were determined (n=92). Moreover, the inhibitory effects of isoprenaline were evaluated following a desensitizing treatment involving long-term (24 h) incubation of mast cells with isoprenaline (10(-6) M) (n=65). A potential influence of polymorphisms on these functional responses was determined by genotyping 11 positions, in the promoter and coding regions, of ADRB2 previously reported as polymorphic. KEY RESULTS: There was no influence of any of the polymorphic positions of ADRB2 on the potency of isoprenaline to inhibit histamine release from mast cells with the exception of position 491C>T (Thr164Ile). There was no influence of any of the polymorphic positions of ADRB2 on the extent of desensitization of the isoprenaline-mediated response following a desensitizing treatment except for position 46G>A (Gly16Arg). Analyses at the haplotype level indicated that there was no influence of haplotype on beta (2)-adrenoceptor-mediated responses in mast cells. CONCLUSIONS AND IMPLICATIONS: These data indicate that certain polymorphisms in ADRB2 influence beta(2)-adrenoceptor-mediated responses in human lung mast cells.
BACKGROUND AND PURPOSE: Previous studies have shown that beta(2)-adrenoceptor-mediated responses in human lung mast cells are highly variable. The aims of the present study were to establish whether polymorphisms of the beta (2)-adrenoceptor gene (ADRB2) influence this variability in (a) beta(2)-adrenoceptor-mediated inhibition and (b) desensitization of beta(2)-adrenoceptor-mediated responses in human lung mast cells. EXPERIMENTAL APPROACH: Mast cells were isolated from human lung tissue. The inhibitory effects of the beta-adrenoceptor agonist, isoprenaline (10(-10)-10(-5) M), on IgE-mediated histamine release from mast cells were determined (n=92). Moreover, the inhibitory effects of isoprenaline were evaluated following a desensitizing treatment involving long-term (24 h) incubation of mast cells with isoprenaline (10(-6) M) (n=65). A potential influence of polymorphisms on these functional responses was determined by genotyping 11 positions, in the promoter and coding regions, of ADRB2 previously reported as polymorphic. KEY RESULTS: There was no influence of any of the polymorphic positions of ADRB2 on the potency of isoprenaline to inhibit histamine release from mast cells with the exception of position 491C>T (Thr164Ile). There was no influence of any of the polymorphic positions of ADRB2 on the extent of desensitization of the isoprenaline-mediated response following a desensitizing treatment except for position 46G>A (Gly16Arg). Analyses at the haplotype level indicated that there was no influence of haplotype on beta (2)-adrenoceptor-mediated responses in mast cells. CONCLUSIONS AND IMPLICATIONS: These data indicate that certain polymorphisms in ADRB2 influence beta(2)-adrenoceptor-mediated responses in human lung mast cells.
Authors: A S Aynacioglu; I Cascorbi; K Güngör; M Ozkur; N Bekir; I Roots; J Brockmöller Journal: Br J Clin Pharmacol Date: 1999-11 Impact factor: 4.335
Authors: B Lipworth; G H Koppelman; A P Wheatley; I Le Jeune; W Coutie; H Meurs; H F Kauffman; D S Postma; I P Hall Journal: Thorax Date: 2002-01 Impact factor: 9.139
Authors: C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205
Authors: Ian P Hall; John D Blakey; Khalid A Al Balushi; Amanda Wheatley; Ian Sayers; Marcus E Pembrey; Susan M Ring; Wendy L McArdle; David P Strachan Journal: Lancet Date: 2006-08-26 Impact factor: 79.321
Authors: Yulia Koryakina; Stacie M Jones; Lawrence E Cornett; Kathryn Seely; Lisa Brents; Paul L Prather; Alexander Kofman; Richard C Kurten Journal: Cell Biol Int Date: 2012 Impact factor: 3.612
Authors: Chengwei Wang; Muhammad T Salam; Talat Islam; Madé Wenten; W James Gauderman; Frank D Gilliland Journal: Pediatrics Date: 2008-06-16 Impact factor: 7.124
Authors: Alexander Kondrashov; Nurul A N Mohd Yusof; Alveera Hasan; Joëlle Goulding; Thusharika Kodagoda; Duc M Hoang; Nguyen T N Vo; Tony Melarangi; Nazanin Dolatshad; Julia Gorelik; Stephen J Hill; Sian E Harding; Chris Denning Journal: Mol Ther Methods Clin Dev Date: 2020-10-27 Impact factor: 6.698